Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026 Amid COVID-19

Strategic Insights -

The global market for anti-inflammatory therapeutics is projected to reach $130.9 billion by 2026, growing at a compound annual growth rate (CAGR) of 4.8% over the analysis period. The market is expected to experience significant growth due to the increasing prevalence of chronic inflammatory diseases, such as arthritis, respiratory diseases, and inflammatory bowel disease, which are driving the demand for effective treatments. The global market for anti-inflammatory therapeutics is estimated to be dominated by the United States, followed by China, Japan, and Europe.

Key Takeaways:

  • The global anti-inflammatory therapeutics market is projected to reach $130.9 billion by 2026, growing at a CAGR of 4.8% over the analysis period.
  • The anti-inflammatory biologics segment is expected to record a 5.2% CAGR and reach $67.4 billion by the end of the analysis period.
  • The U.S. market is estimated to be $28 billion in 2021, while China is forecast to reach $26.1 billion by 2026, growing at a CAGR of 7.4%.
  • The Corticosteroids segment is expected to reach $21.3 billion by 2026, with the USA, Canada, Japan, China, and Europe driving the 3.8% CAGR.
  • The market in Asia-Pacific is forecast to reach $2.8 billion by 2026, while Latin America will expand at a 5.2% CAGR through the analysis period.
  • The Corticosteroids segment is expected to be the fastest-growing in the Asia-Pacific region.
  • The market is expected to experience significant growth due to the increasing prevalence of chronic inflammatory diseases.
  • The global market for anti-inflammatory therapeutics is estimated at $97.8 billion in 2020.
  • The report's Executive Pool is 6613 companies, and the players covered include AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer, Inc.

Statistics:

  • Global Anti-Inflammatory Therapeutics Market: $130.9 billion by 2026 (growing at a CAGR of 4.8% over the analysis period).
  • Anti-inflammatory biologics segment: 5.2% CAGR and $67.4 billion by the end of the analysis period.
  • U.S. market: $28 billion in 2021.
  • China market: $26.1 billion by 2026 (growing at a CAGR of 7.4%).
  • Corticosteroids segment: $21.3 billion by 2026 (driven by the 3.8% CAGR in the USA, Canada, Japan, China, and Europe).
  • Asia-Pacific market: $2.8 billion by 2026.
  • Latin America market: expanding at a 5.2% CAGR through the analysis period.

Sources:

  • Global Industry Analysts Inc. (GIA) report titled "Anti-Inflammatory Therapeutics - Global Market Trajectory & Analytics".
  • StrategyR(TM) platform.
  • LinkedIn: https://www.linkedin.com/company/global-industry-analysts-inc/.
  • Twitter: https://twitter.com/marketbytes.
  • GIA website: www.StrategyR.com